{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:52:45Z","timestamp":1791395565073,"version":"4.3.3"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016610","name":"Andrew McDonough B+ Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejca.2025.116093","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:24:20Z","timestamp":1762388660000},"page":"116093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-738X","authenticated-orcid":false,"given":"Steven G.","family":"DuBois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0708-1670","authenticated-orcid":false,"given":"Lucas","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5729-8819","authenticated-orcid":false,"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet C.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-5285","authenticated-orcid":false,"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Sondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Drezner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Kholmanshikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1808-8584","authenticated-orcid":false,"given":"Nicholas","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Ludwinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-2741","authenticated-orcid":false,"given":"Nicole","family":"Scobie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Pons Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Alvarez Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danelle","family":"Meager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joen","family":"Sveistrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-7789","authenticated-orcid":false,"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5316-6440","authenticated-orcid":false,"given":"Julia","family":"Glade-Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4859-1108","authenticated-orcid":false,"given":"Daniel A.","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6559-3239","authenticated-orcid":false,"given":"Cormac","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":false,"given":"Brenda J.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-3979","authenticated-orcid":false,"given":"Alberto","family":"Pappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-3203","authenticated-orcid":false,"given":"John","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2598-8772","authenticated-orcid":false,"given":"Franca","family":"Ligas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Karres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116093_bib1","doi-asserted-by":"crossref","first-page":"1371345","DOI":"10.3389\/fimmu.2024.1371345","article-title":"GD2-targeting therapy: a comparative analysis of approaches and promising directions","volume":"15","author":"Philippova","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2025.116093_bib2","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116093_bib3","article-title":"A 2035 clinical research vision and roadmap for high-risk neuroblastoma","volume":"e31660","author":"Moreno","year":"2025","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib4","doi-asserted-by":"crossref","first-page":"1249929","DOI":"10.3389\/fphar.2023.1249929","article-title":"Biology of GD2 ganglioside: implications for cancer immunotherapy","volume":"14","author":"Machy","year":"2023","journal-title":"Front Pharm"},{"key":"10.1016\/j.ejca.2025.116093_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010423","article-title":"Ganglioside GD2 enhances the malignant phenotypes of melanoma cells by cooperating with integrins","volume":"23","author":"Yesmin","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2025.116093_bib6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-022-02523-x","article-title":"B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met\/AKT\/mTOR\/IRF-1 axis in neuroblastoma","volume":"41","author":"Sha","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41591-021-01625-x","article-title":"Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication","volume":"28","author":"Theruvath","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116093_bib8","first-page":"976","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1. Nat","volume":"3","author":"Mabe","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2019.02.014","article-title":"EZH2 inhibition in ewing sarcoma upregulates G(D2) expression for targeting with gene-modified T cells","volume":"27","author":"Kailayangiri","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejca.2025.116093_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1164919","article-title":"Anti-GD2 mAb and vorinostat synergize in the treatment of neuroblastoma","volume":"5","author":"Kroesen","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2025.116093_bib11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1471-4159.1991.tb02078.x","article-title":"Gangliosides in human fetal brain","volume":"56","author":"Svennerholm","year":"1991","journal-title":"J Neurochem."},{"key":"10.1016\/j.ejca.2025.116093_bib12","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002293","article-title":"Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic\/therapeutic target in GD2neg\/low neuroblastoma variants","volume":"9","author":"Dondero","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116093_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib16","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1158\/1078-0432.CCR-23-1880","article-title":"GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma","volume":"30","author":"Ciccone","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib17","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","article-title":"Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers","volume":"30","author":"Fischer-Riepe","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12196223","article-title":"A multi-color flow cytometric assay for quantifying dinutuximab binding to neuroblastoma cells in tumor, bone marrow, and blood","volume":"12","author":"Keyel","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2025.116093_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103199","article-title":"Protocol for assessing GD2 on formalin-fixed paraffin-embedded tissue sections using immunofluorescence staining","volume":"5","author":"Kailayangiri","year":"2024","journal-title":"STAR Protoc"},{"key":"10.1016\/j.ejca.2025.116093_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14246051","article-title":"GD2 expression in medulloblastoma and neuroblastoma for personalized immunotherapy: a matter of subtype","volume":"14","author":"Paret","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116093_bib21","article-title":"The ganglioside G(D2) as a circulating tumor biomarker for neuroblastoma","volume":"67","author":"Balis","year":"2020","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib22","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1158\/0008-5472.CAN-18-3340","article-title":"Positron emission tomography detects in Vivo expression of disialoganglioside GD2 in mouse models of primary and metastatic osteosarcoma","volume":"79","author":"Butch","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib23","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1007\/s00259-022-05888-5","article-title":"Anti-GD2 antibody for radiopharmaceutical imaging of osteosarcoma","volume":"49","author":"Fu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2025.116093_bib24","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.7150\/thno.56736","article-title":"Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma","volume":"12","author":"Schmitt","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2025.116093_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2967\/jnumed.122.264626","article-title":"First-in-humans PET\/MRI of In Vivo GD2 expression in osteosarcoma","volume":"64","author":"Trautwein","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2025.116093_bib26","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2967\/jnumed.120.261854","article-title":"131)I-GD2-ch14.18 scintigraphy to evaluate option for radioimmunotherapy in patients with advanced tumors","volume":"63","author":"Zhang","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2025.116093_bib27","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.7150\/thno.92481","article-title":"A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [(64)Cu]Cu-NOTA-ch14.18\/CHO","volume":"14","author":"Trautwein","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejca.2025.116093_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1084\/jem.170.2.511","article-title":"Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release assays","volume":"170","author":"Munn","year":"1989","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2025.116093_bib29","first-page":"144","article-title":"Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib30","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1182\/blood.V73.7.1936.1936","article-title":"GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma","volume":"73","author":"Kushner","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116093_bib31","first-page":"6600","article-title":"Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma","volume":"47","author":"Munn","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib32","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1172\/JCI113426","article-title":"Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro","volume":"81","author":"Cheung","year":"1988","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2025.116093_bib33","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.1987.5.9.1430","article-title":"Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma","volume":"5","author":"Cheung","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0959-8049(94)00413-Y","article-title":"A phase I study of human\/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma","volume":"31A","author":"Handgretinger","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib35","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1200\/JCO.1998.16.6.2169","article-title":"Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma","volume":"16","author":"Yu","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2006.10.3564","article-title":"Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group","volume":"27","author":"Gilman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib37","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1200\/JCO.2000.18.24.4077","volume":"18","author":"Ozkaynak","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020309","article-title":"Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 Trial (HR-NBL1)","volume":"12","author":"Ladenstein","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116093_bib39","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib40","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1038\/s41416-023-02457-x","article-title":"Long-term, continuous infusion of single-agent dinutuximab beta for relapsed\/refractory neuroblastoma: an open-label, single-arm, Phase 2 study","volume":"129","author":"Lode","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib41","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 Anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib42","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.116093_bib43","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(17)30355-8","article-title":"Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial","volume":"18","author":"Mody","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib44","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab With GM-CSF in children with refractory or relapsed neuroblastoma: a report from the children's oncology group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib45","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.22.01273","article-title":"Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan\/temozolomide\/dinutuximab\/granulocyte-macrophage colony-stimulating factor","volume":"41","author":"Lerman","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib46","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","article-title":"A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma","volume":"23","author":"Federico","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194837","article-title":"Early salvage chemo-immunotherapy with irinotecan, temozolomide and naxitamab plus GM-CSF (HITS) for patients with primary refractory high-risk neuroblastoma provide the best chance for long-term outcomes","volume":"15","author":"Munoz","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.116093_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114001","article-title":"Chemo-immunotherapy with dinutuximab beta in patients with relapsed\/progressive high-risk neuroblastoma: does chemotherapy backbone matter?","volume":"202","author":"Raiser","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib49","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1200\/JCO.21.01375","article-title":"Improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy: updated results of a phase II study using hu14.18K322A.","volume":"40","author":"Furman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib50","doi-asserted-by":"crossref","unstructured":"Macy M.E., Naranjo A., Zhang F.F., et al: A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed\/refractory neuroblastoma: A Children\u2019s Oncology Group Report. Presented at the American Society of Clinical Oncology, 2025.","DOI":"10.1200\/JCO.2025.43.16_suppl.10001"},{"key":"10.1016\/j.ejca.2025.116093_bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","article-title":"Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the Children's Oncology Group","volume":"172","author":"Hingorani","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib52","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.21.01916","article-title":"When innovation and commercialization collide: a patient advocate view in neuroblastoma","volume":"40","author":"Bird","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib53","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1158\/1078-0432.CCR-20-3909","article-title":"Long-term follow-up of a phase III study of ch14.18 (Dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032.","volume":"27","author":"Yu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib54","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1200\/JCO.2015.64.9558","article-title":"KIR3DL1 allelic polymorphism and HLA-B epitopes modulate response to anti-GD2 monoclonal antibody in patients with neuroblastoma","volume":"34","author":"Forlenza","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1158\/1078-0432.CCR-17-1767","article-title":"Neuroblastoma patients' KIR and KIR-ligand genotypes influence clinical outcome for dinutuximab-based immunotherapy: a report from the children's oncology group","volume":"24","author":"Erbe","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006530","article-title":"KIR\/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology Group","volume":"11","author":"Erbe","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib57","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.21.02478","article-title":"Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: a report from the children's oncology group","volume":"40","author":"Desai","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib58","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1235108","article-title":"Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD(2) antibody ch14.18\/CHO show higher ADCC levels and improved event-free survival","volume":"5","author":"Siebert","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ejca.2025.116093_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004646","article-title":"Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors","volume":"10","author":"Kalinovsky","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib60","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1158\/1078-0432.CCR-19-0798","article-title":"Antitumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: a children's oncology group phase II study","volume":"25","author":"Shusterman","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib61","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1200\/JCO.2009.27.8861","article-title":"Antitumor activity of hu14.18-IL2 in patients with relapsed\/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study","volume":"28","author":"Shusterman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib62","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/1078-0432.CCR-22-0717","article-title":"Anti-GD2 antibodies conjugated to IL15 and IL21 mediate potent antitumor cytotoxicity against neuroblastoma","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib63","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00259-023-06528-2","article-title":"Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma-a proof of concept study","volume":"51","author":"Liatsou","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2025.116093_bib64","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1158\/1078-0432.CCR-20-2150","article-title":"A self-assembling and disassembling (SADA) bispecific antibody (BsAb) platform for curative two-step pretargeted radioimmunotherapy","volume":"27","author":"Santich","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116093_bib65","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2025.116093_bib66","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","author":"Li","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116093_bib67","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2025.116093_bib68","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116093_bib69","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116093_bib70","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.116093_bib71","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.116093_bib72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","article-title":"Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy","volume":"42","author":"Kaczanowska","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.116093_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1200\/JCO.23.01314","article-title":"Chimeric antigen receptor (CAR) T-cell products for pediatric cancers: why alternative development paths are needed","volume":"42","author":"Rossig","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib74","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1016\/S1470-2045(24)00736-8","article-title":"New models for the development of and access to CAR T-cell therapies for children and adolescents with cancer: an ACCELERATE multistakeholder analysis","volume":"26","author":"Pearson","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008744","article-title":"Targeting refractory\/recurrent neuroblastoma and osteosarcoma with anti-CD3xanti-GD2 bispecific antibody armed T cells","volume":"12","author":"Yankelevich","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.116093_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.20.01892","article-title":"Survival impact of anti-GD2 antibody response in a phase ii ganglioside vaccine trial among patients with high-risk neuroblastoma with prior disease progression","volume":"39","author":"Cheung","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib77","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2000.18.2.376","article-title":"Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2","volume":"18","author":"Foon","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116093_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14235802","article-title":"Immune response and outcome of high-risk neuroblastoma patients immunized with anti-idiotypic antibody ganglidiomab: results from compassionate-use treatments","volume":"14","author":"Klingel","year":"2022","journal-title":"Cancers"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925009797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:02:20Z","timestamp":1769792540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925009797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"alternative-id":["S0959804925009797"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116093","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116093"}}